4 Results for "

BIR2 domain

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "BIR2 domain" in MCE Product Catalog:

61
61 Publications Verification
Cat. No.: HY-15989
CAS No.: 957135-43-2
Target:  

IAP Apoptosis

Research Areas:  

Cancer

SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.
loading...
    loading...
61
61 Publications Verification
Cat. No.: HY-15989A
CAS No.: 2734174-02-6
Target:  

IAP Apoptosis

Research Areas:  

Cancer

SM-164 hydrochloride is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-115865
CAS No.: 2803617-91-4
Purity:  99.31%
Target:  

PROTACs IAP

Research Areas:  

Cancer

XIAP degrader-1 is a PROTAC-like degrader with a Kd value of 1 μM for XIAP. XIAP degrader-1 is metabolized into an active aldehyde species that covalently binds to Cys326 of FBXO22, thereby forming a ternary complex with the BIR2 domain of XIAP. XIAP degrader-1 induces polyubiquitination and proteasomal degradation of XIAP via the ubiquitin-proteasome system, a process dependent on NEDD8 conjugation, the SCF FBXO22 ligase complex, as well as the functional activities of XIAP ligase, E1 and the proteasome .
loading...
    loading...
Cat. No.: HY-123925
CAS No.: 2244988-80-3
CSLP43 is a selective RIPK2 and XIAP inhibitor with an IC50 of 19.9 nM against human RIPK2. CSLP43 binds to the ATP-binding pocket of RIPK2 and disrupts the interaction between RIPK2 and the BIR2 domain of XIAP or cIAP1. CSLP43 inhibits RIPK2 ubiquitination, NOD1-dependent inflammatory signaling pathways, NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. CSLP43 is selective for the NOD1/NOD2 signaling pathway and does not inhibit the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable to research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis and early-onset inflammatory bowel disease .
loading...
    loading...